Sartorius AG and its French-listed arm, Sartorius Stedim Biotech, announced formal mid-term profitability and growth targets on Tuesday, marking the first time either entity has issued structured margin commitments since a downturn in the bioprocessing sector. Both sets of targets take effect from 2027 and outline annual objectives for organic sales growth and underlying EBITDA margin expansion.
At the group level, Sartorius AG reaffirmed a goal of organic sales revenue growth of 8% to 11% per year in constant currencies from 2027, paired with annual underlying EBITDA margin improvements of 50 to 75 basis points. The company reported sales revenue of around 0e3.5 billion for 2025.
Its French-listed unit, Sartorius Stedim Biotech, which reported roughly 0e3 billion in 2025 sales revenue, set a slightly higher organic growth band of 9% to 12% per year, together with annual underlying EBITDA margin expansion of 60 to 85 basis points. Both organizations said they expect to outgrow their addressable markets by 100 to 200 basis points each year.
The internal split of expectations is most notable within Sartorius AG. The Bioprocess Solutions Division is forecast to expand at an annual organic rate of 9% to 12%, with EBITDA margins improving by 60 to 85 basis points per year. By contrast, the Lab Products & Services Division is expected to grow at a slower clip of 5% to 7% annually, with margin gains of 20 to 30 basis points per year - roughly a third of the rate targeted for bioprocessing.
Company projections for addressable market growth were also shared: Sartorius AG estimates overall addressable markets will grow 7% to 9% per year, with bioprocessing markets expanding at 8% to 10% and lab products at 4% to 6% annually. The announcements referenced industry data stating that global biopharma revenues surpassed traditional therapies in 2025 and are expected to account for 57% of global pharma sales by 2030.
Chief Executive Michael Grosse commented in a statement that the biopharma sector is entering a period where "innovation, speed and reliability matter more than ever," and added that in such an environment a sharpened focus is critical. Both companies highlighted process intensification, single-use technologies and analytics as central strategic priorities, and identified advanced therapy solutions and process analytical technologies as emerging areas for growth.
Management also cautioned that forecasting risks have risen, pointing to geopolitical decoupling and changing trade conditions as sources of heightened uncertainty. All targets were presented in constant currencies, and the 2027 effective date leaves 2026 without formal guidance under the new framework.
On workforce size, Sartorius AG employs more than 14,000 people while Sartorius Stedim Biotech has a workforce of more than 10,200.